MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412713 | Name: SLM6031434 free base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SLM6031434 (free base) is an inhibitor of sphingosine kinase type 2 (SphK2). It consists of pedant 1-guanidino-2-phenyloxadiazolylpyrrolidine group.

Chemical Structure

SLM6031434 free base
SLM6031434 free base
CAS#1897379-33-7 (free base)

Theoretical Analysis

MedKoo Cat#: 412713

Name: SLM6031434 free base

CAS#: 1897379-33-7 (free base)

Chemical Formula: C22H30F3N5O2

Exact Mass: 453.2352

Molecular Weight: 453.51

Elemental Analysis: C, 58.27; H, 6.67; F, 12.57; N, 15.44; O, 7.06

Price and Availability

Size Price Availability Quantity
1mg USD 300.00 2 Weeks
5mg USD 515.00 2 weeks
10mg USD 700.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1897379-34-8 (HCl) 1897379-33-7 (free base) 1897381-17-7 (free base)
Synonym
SLM6031434 (free base); (R)-2-(3-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)pyrrolidine-1-carboximidamide
IUPAC/Chemical Name
(S)-2-(3-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)pyrrolidine-1-carboximidamide
InChi Key
ACUOAECMLLBZNL-KRWDZBQOSA-N
InChi Code
InChI=1S/C22H30F3N5O2/c1-2-3-4-5-6-7-13-31-18-11-10-15(14-16(18)22(23,24)25)19-28-20(32-29-19)17-9-8-12-30(17)21(26)27/h10-11,14,17H,2-9,12-13H2,1H3,(H3,26,27)/t17-/m0/s1
SMILES Code
N=C(N)N1CCC[C@H]1C2=NC(C3=CC(C(F)(F)F)=C(OCCCCCCCC)C=C3)=NO2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
SLM6031434 is a SPHK2 inhibitor (Ki = 0.4 μM for the recombinant mouse enzyme). It is selective for SPHK2 over SPHK1 (Kis = >20 μM). It decreases S1P and increases sphingosine levels in U937 monocytic leukemia cells in a concentration-dependent manner. SLM6031434 reduces blood S1P levels in Sphk1-/-, but not Sphk2-/-, mice. SLM6031434 also increases blood S1P levels in wild-type mice and rats.
In vitro activity:
This study found that SphK2 plays a pro-inflammatory role in microglia, and inhibiting it with SLM6031434 contributed to suppressing inflammatory responses. Inhibiting SphK2 with SLM6031434 significantly reduced the lipopolysaccharide (LPS)-induced production of pro-inflammatory cytokines such as tumor necrosis factor-α (TNFα) and interleukin-1β (IL-1β) in BV2 mouse microglia cells. Reference: Int J Mol Sci. 2023 May 9;24(10):8508. https://pubmed.ncbi.nlm.nih.gov/37239854/
In vivo activity:
This study suggests that SK2 inhibition has anti-fibrotic effects, making it a promising target for treating fibrosis in chronic kidney disease. In a mouse model of progressive kidney damage, results showed that mice treated with SLM6031434 and HWG-35D exhibited reduced fibrotic responses compared to those treated with a vehicle control. In SLM6031434 and HWG-35D treated mice, there was decreased collagen accumulation and lower expression of key fibrosis-related proteins. Reference: Cell Signal. 2021 Mar;79:109881. https://pubmed.ncbi.nlm.nih.gov/33301900/

Preparing Stock Solutions

The following data is based on the product molecular weight 453.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Standoli S, Rapino C, Di Meo C, Rudowski A, Kämpfer-Kolb N, Volk LM, Thomas D, Trautmann S, Schreiber Y, Meyer Zu Heringdorf D, Maccarrone M. Sphingosine Kinases at the Intersection of Pro-Inflammatory LPS and Anti-Inflammatory Endocannabinoid Signaling in BV2 Mouse Microglia Cells. Int J Mol Sci. 2023 May 9;24(10):8508. doi: 10.3390/ijms24108508. PMID: 37239854; PMCID: PMC10217805. 2. Schwalm S, Beyer S, Hafizi R, Trautmann S, Geisslinger G, Adams DR, Pyne S, Pyne N, Schaefer L, Huwiler A, Pfeilschifter J. Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis. Cell Signal. 2021 Mar;79:109881. doi: 10.1016/j.cellsig.2020.109881. Epub 2020 Dec 8. PMID: 33301900.
In vitro protocol:
1. Standoli S, Rapino C, Di Meo C, Rudowski A, Kämpfer-Kolb N, Volk LM, Thomas D, Trautmann S, Schreiber Y, Meyer Zu Heringdorf D, Maccarrone M. Sphingosine Kinases at the Intersection of Pro-Inflammatory LPS and Anti-Inflammatory Endocannabinoid Signaling in BV2 Mouse Microglia Cells. Int J Mol Sci. 2023 May 9;24(10):8508. doi: 10.3390/ijms24108508. PMID: 37239854; PMCID: PMC10217805.
In vivo protocol:
1. Schwalm S, Beyer S, Hafizi R, Trautmann S, Geisslinger G, Adams DR, Pyne S, Pyne N, Schaefer L, Huwiler A, Pfeilschifter J. Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis. Cell Signal. 2021 Mar;79:109881. doi: 10.1016/j.cellsig.2020.109881. Epub 2020 Dec 8. PMID: 33301900.
1: Sibley CD, Morris EA, Kharel Y, Brown AM, Huang T, Bevan DR, Lynch KR, Santos WL. Discovery of a Small Side Cavity in Sphingosine Kinase 2 that Enhances Inhibitor Potency and Selectivity. J Med Chem. 2020 Feb 13;63(3):1178-1198. doi: 10.1021/acs.jmedchem.9b01508. Epub 2020 Jan 28. PMID: 31895563; PMCID: PMC8215855. 2: Schwalm S, Beyer S, Hafizi R, Trautmann S, Geisslinger G, Adams DR, Pyne S, Pyne N, Schaefer L, Huwiler A, Pfeilschifter J. Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti- fibrotic treatment options in a mouse model of tubulointerstitial fibrosis. Cell Signal. 2021 Mar;79:109881. doi: 10.1016/j.cellsig.2020.109881. Epub 2020 Dec 8. PMID: 33301900. 3: Imeri F, Stepanovska Tanturovska B, Schwalm S, Saha S, Zeng-Brouwers J, Pavenstädt H, Pfeilschifter J, Schaefer L, Huwiler A. Loss of sphingosine kinase 2 enhances Wilm's tumor suppressor gene 1 and nephrin expression in podocytes and protects from streptozotocin-induced podocytopathy and albuminuria in mice. Matrix Biol. 2021 Apr;98:32-48. doi: 10.1016/j.matbio.2021.05.003. Epub 2021 May 17. PMID: 34015468. 4: Standoli S, Rapino C, Di Meo C, Rudowski A, Kämpfer-Kolb N, Volk LM, Thomas D, Trautmann S, Schreiber Y, Meyer Zu Heringdorf D, Maccarrone M. Sphingosine Kinases at the Intersection of Pro-Inflammatory LPS and Anti-Inflammatory Endocannabinoid Signaling in BV2 Mouse Microglia Cells. Int J Mol Sci. 2023 May 9;24(10):8508. doi: 10.3390/ijms24108508. PMID: 37239854; PMCID: PMC10217805. 5: Wallen TE, Morris M, Ammann A, Baucom MR, Price A, Schuster R, Makley AT, Goodman MD. Platelet Function is Independent of Sphingolipid Manipulation. J Surg Res. 2024 Aug;300:25-32. doi: 10.1016/j.jss.2024.04.063. Epub 2024 May 24. PMID: 38795670. 6: Prell A, Wigger D, Huwiler A, Schumacher F, Kleuser B. The sphingosine kinase 2 inhibitors ABC294640 and K145 elevate (dihydro)sphingosine 1-phosphate levels in various cells. J Lipid Res. 2024 Oct;65(10):100631. doi: 10.1016/j.jlr.2024.100631. Epub 2024 Aug 23. PMID: 39182604; PMCID: PMC11465068.

View History

Sodium lauroyl glutamate

Sodium lauroyl glutamate